suPARnostic® is a prognostic biomarker useful for risk stratification of acute medical patients in the Emergency Department.

Important clinical benefits include;

  • Prioritization: Identifies patients who can be discharged after treatment
  • Safety: Identifies high-risk patients wih unaffected vital signs
  • Cost savings: Shortens the average patient-length-of-stay and reduces
    the cost of healthcare


The suPARnostic® TurbiLatex product is CE-IVD approved for the Roche Diagnostics Cobas c500 and c700 series.

The suPARnostic® TurbiLatex test is validtated on the Roche Cobas c501/c502/c701/c702 biochemistry analyzer.

ViroGates is validating the suPARnostic® TurbiLatex test on other biochemistry analyzers such as Siemens Atellica, Siemens Advia XPT, Abbott Architect and Abbott Alinity. More information in Q3-Q4 2019.